{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T17:04:54Z","timestamp":1790701494882,"version":"4.1.0"},"reference-count":42,"publisher":"IMR Press","issue":"9","license":[{"start":{"date-parts":[[2026,9,20]],"date-time":"2026-09-20T00:00:00Z","timestamp":1789862400000},"content-version":"unspecified","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"funder":[{"name":"Pirogov Russian National Research Medical University","award":["124020900031-0"],"award-info":[{"award-number":["124020900031-0"]}],"id":[{"id":"https:\/\/ror.org\/018159086","id-type":"ROR","asserted-by":"crossref"}]},{"name":"Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences","award":["075-00224-26-02"],"award-info":[{"award-number":["075-00224-26-02"]}],"id":[{"id":"https:\/\/ror.org\/05qrfxd25","id-type":"ROR","asserted-by":"crossref"}]}],"content-domain":{"domain":[],"crossmark-restriction":false},"short-container-title":["Front. Biosci. (Landmark Ed)"],"abstract":"<jats:p>Objective: Recent data show that there are direct relationships between mitochondrial activity, cancer progression, and chemoresistance. Venetoclax (Ven) is a mitochondria-targeted chemotherapeutic drug, which facilitates apoptosis by selectively inhibiting the antiapoptotic protein Bcl-2. Ven exhibits a dual effect, affecting not only mitochondria but also the cell drug resistance system. There is also evidence indicating that cancer cells develop resistance to Ven, which is mediated by the upregulation of antiapoptotic proteins, simultaneous activation of multiple signaling pathways, an alteration in the cellular and mitochondrial metabolism, and other defensive mechanisms. The influence of Ven on the opening of the mitochondrial permeability transition pore (mPTP), a key event in the induction of mitochondria-dependent cell death, has not been previously studied. Methods: The effect of Ven on calcium-induced mPTP opening, respiration, and reactive oxygen species (ROS) production was examined in isolated rat liver mitochondria, using cation-selective electrodes, as well as fluorescent and chemiluminescent methods. Results: Ven was found to have a protective effect against the Ca2+-induced mPTP opening, increasing the threshold calcium concentrations and the calcium load that activate pore opening. A comparison with the known mPTP inhibitors ADP, bongkrekic acid (BA), cyclosporine A (Cs), oligomycin, used separately and in combination with Ven, showed a similarity of the effect of Ven (at a concentration of 50 \u00b5M) to the effect of BA (20 \u00b5M). The effects of both were prevented by carboxyatractyloside (CATR). Also, the protective effect of Ven, as well as that of BA, was completely eliminated by 2-thenoyltrifluoroacetone (TTFA), an inhibitor of the ubiquinone-binding site of succinate dehydrogenase complex at low concentrations (5 \u00b5M and 50 \u00b5M under the oxidation of succinate and NAD-dependent substrates, respectively). Simultaneously, Ven decreased the ROS production induced by TTFA under the same conditions. Conclusions: Ven shows two protective activities, namely, the inhibition of mPTP opening and the suppression of ROS production in mitochondria, which may be additional causes of the development of drug resistance. The results of the TTFA test are consistent with the data on the dependence of Ven resistance on the state of the respiratory chain.<\/jats:p>","DOI":"10.31083\/fbl55451","type":"journal-article","created":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:21:51Z","timestamp":1790698911000},"source":"Crossref","is-referenced-by-count":0,"title":["The Protective Effect of Venetoclax on the Calcium-Induced Mitochondrial Pore and ROS Production as a New Possible Factor Contributing to Drug Resistance"],"prefix":"10.31083","volume":"31","author":[{"ORCID":"https:\/\/orcid.org\/0000-0001-9215-7387","authenticated-orcid":true,"given":"Alexey G.","family":"Kruglov","sequence":"first","affiliation":[{"name":"Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, 142290 Pushchino, Moscow Region, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-4998-9991","authenticated-orcid":true,"given":"Tatiana A.","family":"Fedotcheva","sequence":"additional","affiliation":[{"name":"Science Research Laboratory of Molecular Pharmacology, Medical Biological Faculty, Pirogov Russian National Research Medical University, Ministry of Health of the Russian Federation, 117997 Moscow, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-5446-2460","authenticated-orcid":true,"given":"Nadezhda I.","family":"Fedotcheva","sequence":"additional","affiliation":[{"name":"Institute of Theoretical and Experimental Biophysics, Russian Academy of Sciences, 142290 Pushchino, Moscow Region, Russia"}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"16242","published-online":{"date-parts":[[2026,9,20]]},"reference":[{"key":"ref1","doi-asserted-by":"publisher","unstructured":"Morisaki T, Katano M. Mitochondria-targeting therapeutic strategies for overcoming chemoresistance and progression of cancer. Current Medicinal Chemistry. 2003; 10: 2517\u20132521.","DOI":"10.2174\/0929867033456431"},{"key":"ref2","doi-asserted-by":"publisher","unstructured":"Mukherjee S, Bhatti GK, Chhabra R, Reddy PH, Bhatti JS. Targeting mitochondria as a potential therapeutic strategy against chemoresistance in cancer. Biomedicine & Pharmacotherapy = Biomedecine & Pharmacotherapie. 2023; 160: 114398.","DOI":"10.1016\/j.biopha.2023.114398"},{"key":"ref3","doi-asserted-by":"publisher","unstructured":"Genovese I, Carinci M, Modesti L, Aguiari G, Pinton P, Giorgi C. Mitochondria: Insights into Crucial Features to Overcome Cancer Chemoresistance. International Journal of Molecular Sciences. 2021; 22: 4770.","DOI":"10.3390\/ijms22094770"},{"key":"ref4","doi-asserted-by":"publisher","unstructured":"Winter JM, Yadav T, Rutter J. Stressed to death: Mitochondrial stress responses connect respiration and apoptosis in cancer. Molecular Cell. 2022; 82: 3321\u20133332.","DOI":"10.1016\/j.molcel.2022.07.012"},{"key":"ref5","doi-asserted-by":"publisher","unstructured":"Goebel J, Chmielewski J, Hrycyna CA. The roles of the human ATP-binding cassette transporters P-glycoprotein and ABCG2 in multidrug resistance in cancer and at endogenous sites: future opportunities for structure-based drug design of inhibitors. Cancer Drug Resistance (alhambra, Calif.). 2021; 4: 784\u2013804.","DOI":"10.20517\/cdr.2021.19"},{"key":"ref6","doi-asserted-by":"publisher","unstructured":"Seeger MA, van Veen HW. Molecular basis of multidrug transport by ABC transporters. Biochimica Et Biophysica Acta. 2009; 1794: 725\u2013737.","DOI":"10.1016\/j.bbapap.2008.12.004"},{"key":"ref7","doi-asserted-by":"publisher","unstructured":"Xiao H, Zheng Y, Ma L, Tian L, Sun Q. Clinically-Relevant ABC Transporter for Anti-Cancer Drug Resistance. Frontiers in Pharmacology. 2021; 12: 648407.","DOI":"10.3389\/fphar.2021.648407"},{"key":"ref8","doi-asserted-by":"publisher","unstructured":"Zhao L, Deng X, Li Y, Hu J, Xie L, Shi F, et al. Conformational change of adenine nucleotide translocase-1 mediates cisplatin resistance induced by EBV-LMP1. EMBO Molecular Medicine. 2021; 13: e14072.","DOI":"10.15252\/emmm.202114072"},{"key":"ref9","doi-asserted-by":"publisher","unstructured":"Hu K, Lai Y, Zhou J, Hu C, Guo S, Zhang H, et al. Aberrant activation of adenine nucleotide translocase 3 promotes progression and chemoresistance in multiple myeloma dependent on PINK1 transport. International Journal of Biological Sciences. 2025; 21: 233\u2013250.","DOI":"10.7150\/ijbs.101850"},{"key":"ref10","doi-asserted-by":"publisher","unstructured":"Fedotcheva T, Shimanovsky N, Fedotcheva N. Involvement of Multidrug Resistance Modulators in the Regulation of the Mitochondrial Permeability Transition Pore. Membranes. 2022; 12: 890.","DOI":"10.3390\/membranes12090890"},{"key":"ref11","doi-asserted-by":"publisher","unstructured":"Fedotcheva TA, Kruglov AG, Fedotcheva NI. Influence of Tariquidar, an ABC Transporter Inhibitor, on the Ca2+-Dependent Mitochondrial Permeability Transition Pore. Pharmaceuticals (basel, Switzerland). 2025; 18: 924.","DOI":"10.3390\/ph18060924"},{"key":"ref12","doi-asserted-by":"publisher","unstructured":"Mukherjee N, Sheetz J, Shellman YG. Targeting the BCL2 Family: Advances and Challenges in BH3 Mimetic-Based Therapies. International Journal of Molecular Sciences. 2025; 26: 9859.","DOI":"10.3390\/ijms26209859"},{"key":"ref13","doi-asserted-by":"publisher","unstructured":"Maffeo B, Panuzzo C, Moraca A, Cilloni D. A Leukemic Target with a Thousand Faces: The Mitochondria. International Journal of Molecular Sciences. 2023; 24: 13069.","DOI":"10.3390\/ijms241713069"},{"key":"ref14","doi-asserted-by":"publisher","unstructured":"Roca-Portoles A, Rodriguez-Blanco G, Sumpton D, Cloix C, Mullin M, Mackay GM, et al. Venetoclax causes metabolic reprogramming independent of BCL-2 inhibition. Cell Death & Disease. 2020; 11: 616.","DOI":"10.1038\/s41419-020-02867-2"},{"key":"ref15","doi-asserted-by":"publisher","unstructured":"Wang JQ, Li JY, Teng QX, Lei ZN, Ji N, Cui Q, et al. Venetoclax, a BCL-2 Inhibitor, Enhances the Efficacy of Chemotherapeutic Agents in Wild-Type ABCG2-Overexpression-Mediated MDR Cancer Cells. Cancers. 2020; 12: 466.","DOI":"10.3390\/cancers12020466"},{"key":"ref16","doi-asserted-by":"publisher","unstructured":"Ibrahim MAA, Badr EAA, Abdelrahman AHM, Almansour NM, Shawky AM, Mekhemer GAH, et al. Prospective Drug Candidates as Human Multidrug Transporter ABCG2 Inhibitors: an In Silico Drug Discovery Study. Cell Biochemistry and Biophysics. 2021; 79: 189\u2013200.","DOI":"10.1007\/s12013-021-00985-y"},{"key":"ref17","doi-asserted-by":"publisher","unstructured":"Weiss J, Gajek T, K\u00f6hler B, Haefeli W. Venetoclax (ABT-199) Might Act as a Perpetrator in Pharmacokinetic Drug\u2013Drug Interactions. Pharmaceutics. 2016; 8: 5.","DOI":"10.3390\/pharmaceutics8010005"},{"key":"ref18","doi-asserted-by":"publisher","unstructured":"Liu J, Chen Y, Yu L, Yang L. Mechanisms of venetoclax resistance and solutions. Frontiers in Oncology. 2022; 12: 1005659.","DOI":"10.3389\/fonc.2022.1005659"},{"key":"ref19","doi-asserted-by":"publisher","unstructured":"Bajpai R, Sharma A, Achreja A, Edgar CL, Wei C, Siddiqa AA, et al. Electron transport chain activity is a predictor and target for venetoclax sensitivity in multiple myeloma. Nature Communications. 2020; 11: 1228.","DOI":"10.1038\/s41467-020-15051-z"},{"key":"ref20","doi-asserted-by":"publisher","unstructured":"Cartes-Saavedra B, Ghosh A, Hajn\u00f3czky G. The roles of mitochondria in global and local intracellular calcium signalling. Nature Reviews. Molecular Cell Biology. 2025; 26: 456\u2013475.","DOI":"10.1038\/s41580-024-00820-1"},{"key":"ref21","doi-asserted-by":"publisher","unstructured":"Bernardi P, Gerle C, Halestrap AP, Jonas EA, Karch J, Mnatsakanyan N, et al. Identity, structure, and function of the mitochondrial permeability transition pore: controversies, consensus, recent advances, and future directions. Cell Death and Differentiation. 2023; 30: 1869\u20131885.","DOI":"10.1038\/s41418-023-01187-0"},{"key":"ref22","doi-asserted-by":"publisher","unstructured":"Kruglov AG, Nikiforova AB. The Switching of the Type of a ROS Signal from Mitochondria: The Role of Respiratory Substrates and Permeability Transition. Antioxidants (basel, Switzerland). 2024; 13: 1317.","DOI":"10.3390\/antiox13111317"},{"key":"ref23","doi-asserted-by":"publisher","unstructured":"Towne V, Will M, Oswald B, Zhao Q. Complexities in horseradish peroxidase-catalyzed oxidation of dihydroxyphenoxazine derivatives: appropriate ranges for pH values and hydrogen peroxide concentrations in quantitative analysis. Analytical Biochemistry. 2004; 334: 290\u2013296.","DOI":"10.1016\/j.ab.2004.07.037"},{"key":"ref24","doi-asserted-by":"publisher","unstructured":"SUZUKI N, SUETSUNA K, MASHIKO S, YODA B, NOMOTO T, TOYA Y, et al. Reaction rates for the chemiluminescence of Cypridina luciferin analogues with superoxide: A quenching experiment with superoxide dismutase. Agricultural and Biological Chemistry. 1991; 55: 157\u2013160.","DOI":"10.1271\/bbb1961.55.157"},{"key":"ref25","doi-asserted-by":"publisher","unstructured":"Yamaguchi S, Kishikawa N, Ohyama K, Ohba Y, Kohno M, Masuda T, et al. Evaluation of chemiluminescence reagents for selective detection of reactive oxygen species. Analytica Chimica Acta. 2010; 665: 74\u201378.","DOI":"10.1016\/j.aca.2010.03.025"},{"key":"ref26","doi-asserted-by":"publisher","unstructured":"Teranishi K, Hisamatsu M, Yamada T. Chemiluminescence of 2\u2010methyl\u20106\u2010arylimidazo [1, 2\u2010a] pyrazin\u20103 (7H)\u2010one in protic solvents: electron\u2010donating substituent effect on the formation of the neutral singlet excited\u2010state molecule. Luminescence. 1999; 14: 297\u2013302. <297::AID-BIO574>3.0.CO;2-Y","DOI":"10.1002\/(SICI)1522-7243(199911\/12)14:6"},{"key":"ref27","doi-asserted-by":"publisher","unstructured":"Kruglov AG, Nikiforova AB, Shatalin YV, Shubina VV, Fisyuk AS, Akatov VS. Sulfur-containing compounds quench 3,7-dihydro-2-methyl-6-(4-methoxyphenyl)imidazol[1,2-a]pyrazine-3-one chemiluminescence: Discrimination between true antioxidants and quenchers using xanthine oxidase. Analytical Biochemistry. 2010; 406: 230\u2013232.","DOI":"10.1016\/j.ab.2010.07.001"},{"key":"ref28","doi-asserted-by":"publisher","unstructured":"Klener P, Sovilj D, Renesova N, Andera L. BH3 Mimetics in Hematologic Malignancies. International Journal of Molecular Sciences. 2021; 22: 10157.","DOI":"10.3390\/ijms221810157"},{"key":"ref29","doi-asserted-by":"publisher","unstructured":"Garciaz S, Saillard C, Hicheri Y, Hospital MA, Vey N. Venetoclax in Acute Myeloid Leukemia: Molecular Basis, Evidences for Preclinical and Clinical Efficacy and Strategies to Target Resistance. Cancers. 2021; 13: 5608.","DOI":"10.3390\/cancers13225608"},{"key":"ref30","doi-asserted-by":"publisher","unstructured":"Croce CM, Tait SWG, Garcia-S\u00e1ez AJ, Villunger A, Letai A, Walter HS, et al. What does BCL-2 do? From new molecular insights to the clinical implications. Cell Death and Differentiation. 2026; 33: 673\u2013693.","DOI":"10.1038\/s41418-025-01607-3"},{"key":"ref31","doi-asserted-by":"publisher","unstructured":"Liu D, Liu Z, Hu Y, Xiong W, Wang D, Zeng Z. MOMP: A critical event in cell death regulation and anticancer treatment. Biochimica Et Biophysica Acta. Reviews on Cancer. 2025; 1880: 189280.","DOI":"10.1016\/j.bbcan.2025.189280"},{"key":"ref32","doi-asserted-by":"publisher","unstructured":"Morris JL, Gillet G, Prudent J, Popgeorgiev N. Bcl-2 Family of Proteins in the Control of Mitochondrial Calcium Signalling: An Old Chap with New Roles. International Journal of Molecular Sciences. 2021; 22: 3730.","DOI":"10.3390\/ijms22073730"},{"key":"ref33","doi-asserted-by":"publisher","unstructured":"Sheth AI, Althoff MJ, Tolison H, Engel K, Amaya ML, Krug AE, et al. Targeting Acute Myeloid Leukemia Stem Cells through Perturbation of Mitochondrial Calcium. Cancer Discovery. 2024; 14: 1922\u20131939.","DOI":"10.1158\/2159-8290.CD-23-1145"},{"key":"ref34","doi-asserted-by":"publisher","unstructured":"Palominos C, Fuentes-Retamal S, Salazar JP, Guzm\u00e1n-Rivera D, Correa P, Mellado M, et al. Mitochondrial bioenergetics as a cell fate rheostat for responsive to Bcl-2 drugs: New cues for cancer chemotherapy. Cancer Letters. 2024; 594: 216965.","DOI":"10.1016\/j.canlet.2024.216965"},{"key":"ref35","doi-asserted-by":"publisher","unstructured":"Haworth RA, Hunter DR. Control of the mitochondrial permeability transition pore by high-affinity ADP binding at the ADP\/ATP translocase in permeabilized mitochondria. Journal of Bioenergetics and Biomembranes. 2000; 32: 91\u201396.","DOI":"10.1023\/a:1005568630151"},{"key":"ref36","doi-asserted-by":"publisher","unstructured":"Zhao L, Tang M, Bode AM, Liao W, Cao Y. ANTs and cancer: Emerging pathogenesis, mechanisms, and perspectives. Biochimica Et Biophysica Acta. Reviews on Cancer. 2021; 1875: 188485.","DOI":"10.1016\/j.bbcan.2020.188485"},{"key":"ref37","doi-asserted-by":"publisher","unstructured":"Lytovchenko O, Kunji ERS. Expression and putative role of mitochondrial transport proteins in cancer. Biochimica Et Biophysica Acta. Bioenergetics. 2017; 1858: 641\u2013654.","DOI":"10.1016\/j.bbabio.2017.03.006"},{"key":"ref38","doi-asserted-by":"publisher","unstructured":"Kharechkina ES, Nikiforova AB, Belosludtsev KN, Rokitskaya TI, Antonenko YN, Kruglov AG. Pioglitazone Is a Mild Carrier-Dependent Uncoupler of Oxidative Phosphorylation and a Modulator of Mitochondrial Permeability Transition. Pharmaceuticals (basel, Switzerland). 2021; 14: 1045.","DOI":"10.3390\/ph14101045"},{"key":"ref39","doi-asserted-by":"publisher","unstructured":"Walter L, Miyoshi H, Leverve X, Bernard P, Fontaine E. Regulation of the mitochondrial permeability transition pore by ubiquinone analogs. A progress report. Free Radical Research. 2002; 36: 405\u2013412.","DOI":"10.1080\/10715760290021252"},{"key":"ref40","doi-asserted-by":"publisher","unstructured":"Fontaine E, Eriksson O, Ichas F, Bernardi P. Regulation of the permeability transition pore in skeletal muscle mitochondria. Modulation By electron flow through the respiratory chain complex i. The Journal of Biological Chemistry. 1998; 273: 12662\u201312668.","DOI":"10.1074\/jbc.273.20.12662"},{"key":"ref41","doi-asserted-by":"publisher","unstructured":"Kruspig B, Valter K, Skender B, Zhivotovsky B, Gogvadze V. Targeting succinate:ubiquinone reductase potentiates the efficacy of anticancer therapy. Biochimica Et Biophysica Acta. 2016; 1863: 2065\u20132071.","DOI":"10.1016\/j.bbamcr.2016.04.026"},{"key":"ref42","doi-asserted-by":"publisher","unstructured":"Dinu Iacob A, Confederat LG, Dragostin I, Morariu ID, Tutunaru D, Dragostin OM. Synergism of Synthetic Sulfonamides and Natural Antioxidants for the Management of Diabetes Mellitus Associated with Oxidative Stress. Current Issues in Molecular Biology. 2025; 47: 709.","DOI":"10.3390\/cimb47090709"}],"container-title":["Frontiers in Bioscience-Landmark"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/9\/10.31083\/FBL55451","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,9,29]],"date-time":"2026-09-29T16:21:59Z","timestamp":1790698919000},"score":1,"resource":{"primary":{"URL":"https:\/\/www.imrpress.com\/journal\/FBL\/31\/9\/10.31083\/FBL55451"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,9,20]]},"references-count":42,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2026]]}},"alternative-id":["S2768-6701(26)02278-1"],"URL":"https:\/\/doi.org\/10.31083\/fbl55451","relation":{},"ISSN":["2768-6701","2768-6698"],"issn-type":[{"value":"2768-6701","type":"print"},{"value":"2768-6698","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,9,20]]},"article-number":"55451"}}